---
layout: post
title: "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:35:18 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-00837
original_published: 2023-01-18 00:00:00 +0000
significance: 8.00
---

# Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** January 18, 2023 00:00 UTC
**Document Number:** 2023-00837

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases." This guidance is intended to assist sponsors in identifying the optimal dosage(s) for human prescription drugs or biological products for the treatment of oncologic diseases during clinical development prior to submitting an application for approval for a new indication and usage. This guidance does not address selection of the starting dosage for first-in-human trials nor does it address dosage optimization for radiopharmaceuticals, cellular and gene therapy products, microbiota, or cancer vaccines.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/01/18/2023-00837/optimizing-the-dosage-of-human-prescription-drugs-and-biological-products-for-the-treatment-of)
- API: https://www.federalregister.gov/api/v1/documents/2023-00837

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
